Looking To Compete With BioMarin, Ascendis Continues Its Growth Story

 
• By Joseph Haas
  
Ascendis posted sales growth in 2025, with a new product approval expected in 2026 (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business